Hormonal
Individual metabolic and hormonal adaptations, including somatotype-specific responses and adaptive thermogenesis, drive significant variability in weight management outcomes, rendering the 'calories in, calories out' model insufficient for personalized strategies.
Stop assuming that a calorie is just a calorie for everyone. Your body's hormonal and metabolic response to food and restriction is unique. To succeed, you need to move beyond simple calorie counting and consider personalized strategies like precision nutrition, which may involve analyzing your metabolic profile, hormonal status, and even genetic factors to tailor your diet and exercise.
The global rise in obesity underscores the need for effective weight management strategies that address individual metabolic and hormonal variability, moving beyond the simplistic 'calories in, calories out' model.
Why this rating
This is a narrative review synthesizing multiple studies; it cites specific trials but does not present new primary data.
Source
Beyond Calories: Individual Metabolic and Hormonal Adaptations Driving Variability in Weight Management—A State-of-the-Art Narrative Review
Nikolaos Theodorakis et al. · International Journal of Molecular Sciences · 2024
DOI 10.3390/ijms252413438
More from this paper
- Caloric restriction triggers adaptive thermogenesis, including reduced BMR/RMR, hormonal shifts (lowered T3, leptin, increased ghrelin), and increased appetite, which persist long-term and contribute to weight regain.Good
- Somatotypes (ectomorph, mesomorph, endomorph) correspond to distinct metabolic and hormonal profiles that influence individual responses to diet and exercise, suggesting tailored interventions are more effective.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →